 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
 |
 |
 |
 |
|
Analyst Conference Summaries
Avidity Biosciences
RNA
conference date: August 8, 2023 (press relase only)
Avidity Biosciences Has A Promising RNA Therapy Platform [January 12, 2020 at Seeking Alpha]
| 2023 | |||
| Avidity Biosciences Q4 2022 |
Avidity Biosciences Q1 2023 |
Avidity Biosciences Q1 2023 |
|
| Feb. 28, 2023 | May 9, 2023 | Aug. 8, 2023 | |
| 2022 | |||
| Avidity Biosciences Q4 2021 |
Avidity Biosciences Q1 2022 |
Avidity Biosciences Q2 2022 |
Avidity Biosciences Q3 2022 |
| March 1, 2022 | May 10, 2022 | Aug. 9, 2022 | Nov. 8, 2022 |
| 2021 | |||
| Avidity Biosciences Q4 2020 |
Avidity Biosciences Q1 2021 |
Avidity Biosciences Q2 2021 Press Release |
Avidity Biosciences Q3 2021 summary |
| March 16, 2021 | May 12, 2021 | August 9, 2021 | November 9, 2021 |
Avidity Biosciences (RNA) is a preclinical-stage biotechnology company specializing in a novel RNA therapy platform, antibody oligonucleotide conjugates or AOCs, for diseases caused by genetic mutations.
More Analyst Conference Pages:
| AGEN |
| AGIO |
| ALNY |
| AMAT |
| AMGN |
| APRE |
| ARWR |
| BIIB |
| BMY |
| CLDX |
| CDTX |
| FATE |
| GILD |
| GLYC |
| ILMN |
| INO |
| IONS |
| MCHP |
| MRNA |
| PLX |
| REGN |
| SAGE |
| SGEN |
| VRTX |
| VSTM |
| WBA |
Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.
Copyright 2023 William P. Meyers